New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:48 EDTABT, PCYCPharmacyclics shares have 90% upside potential, says Deutsche Bank
Deutsche Bank believes shares of Pharmacyclics (PCYC) have 90% upside potential over the next 12 months following the recent pullback. Deutsche attributes to the recent pullback to fears around Abbott's (ABT) data for ABT199 at ASCO and weekly scripts that came in lower than some investor expectations. The firm has a Buy rating on Pharmacyclics with a $180 price target.
News For PCYC;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:24 EDTABTMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTABTTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTABTMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
07:24 EDTPCYCStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
March 23, 2015
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use